CASI Pharmaceuticals sells Alesta stake for $5.9M

CASI received about US$5.9M net cash at closing, with possible additional contingent milestone payments, while CID-103 rights remain unchanged.

Rhea-AI Filing Summary

CASI Pharmaceuticals, Inc. (CASIF) reported that it has sold its equity interests in Alesta Therapeutics B.V. to BioMarin Pharmaceutical Inc. under a Share Purchase Agreement, with the transaction closing on August 31, 2026. CASI received approximately US$5.9 million in net cash proceeds at closing and may receive additional contingent payments tied to specified development and regulatory milestones, though these future payments are not assured and remain subject to the transaction agreement.

Alesta completed a spin-out of all non-ALE1 assets to a new entity prior to closing, and BioMarin’s acquisition was structured to retain the ALE1 asset within Alesta. CASI stated that its existing licensed rights to CID-103 remain unchanged following this transaction.

Key Figures

Net cash proceeds at closing: US$5.9 million Transaction closing date: August 31, 2026 Form month: September 2026 +1 more

4 metrics

Net cash proceeds at closing US$5.9 million Cash received by CASI from sale of its equity interests in Alesta at closing

Transaction closing date August 31, 2026 Closing date of BioMarin’s acquisition of Alesta and CASI’s sale of its equity interests

Form month September 2026 Reporting month for the Form 6-K submitted by CASI Pharmaceuticals

Registration Statements referenced File No. 333-283998 and 333-281621 Form F-3 registration statements into which this 6-K information is incorporated by reference

Key Terms

Share Purchase Agreement, contingent payments, spin-out, forward-looking statements, +1 more

5 terms

Share Purchase Agreement financial

"in connection with BioMarin’s acquisition of Alesta pursuant to a Share Purchase Agreement"

A share purchase agreement is a written contract that outlines the terms and conditions for buying and selling shares of a company. It specifies details like the price, number of shares, and any special conditions, ensuring both buyer and seller agree on the transaction. For investors, it provides clarity and legal protection, making sure the purchase is clear and enforceable.

contingent payments financial

"may be entitled to receive its allocable portion of additional contingent payments"

Contingent payments are future sums a buyer agrees to pay a seller only if specified events occur, such as meeting revenue targets, regulatory approval, or achieving performance milestones. For investors, they matter because they shift some price risk from buyer to seller and can change a company’s expected cash flow and valuation — like paying a bonus only if a project succeeds, which affects how much value is really being bought.

spin-out financial

"Prior to the closing, Alesta completed the spin-out of all non-ALE1 assets"

A spin-out is when a company separates part of its operations, assets, or a business unit into a new, independent company and gives existing shareholders an ownership stake in the new entity. Think of it like slicing a specific product line out of a larger store and opening it as its own shop; investors watch spin-outs because they can reveal the true value of the separated business, allow focused management, change risk profiles, and affect share value or ownership stakes.

forward-looking statements regulatory

"This announcement contains forward-looking statements"

Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.

U.S. Private Securities Litigation Reform Act of 1995 regulatory

"made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995"

A federal law that changed the rules for suing companies over securities claims by making it harder to bring class-action lawsuits and by protecting certain forward-looking statements. Think of it as a rulebook that raises the bar for plaintiffs to show clear evidence of wrongdoing and gives companies limited shelter for predictions, which matters to investors because it can reduce litigation risk, legal costs, and volatility tied to lawsuit headlines.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What transaction did CASI Pharmaceuticals (CASIF) announce in this Form 6-K?

CASI Pharmaceuticals announced that it sold its equity interests in Alesta Therapeutics B.V. to BioMarin Pharmaceutical Inc. under a Share Purchase Agreement, with the transaction closing on August 31, 2026.

How much cash did CASIF receive from the sale of its Alesta equity interests?

CASI Pharmaceuticals reported receiving approximately US$5.9 million in net cash proceeds at closing from the sale of its equity interests in Alesta Therapeutics B.V. to BioMarin Pharmaceutical Inc.

Are there potential additional payments to CASIF from the Alesta transaction?

Yes. CASI Pharmaceuticals may receive its allocable portion of additional contingent payments if specified development and regulatory milestones are achieved, although these payments are subject to the transaction agreement and are not assured.

Did the Alesta transaction affect CASIF’s rights to CID-103?

No. CASI Pharmaceuticals stated that its existing licensed rights to CID-103 remain unchanged as a result of the sale of its Alesta equity interests and BioMarin’s acquisition structure.

What happened to Alesta’s non-ALE1 assets in the CASIF–BioMarin deal?

Before closing, Alesta completed a spin-out of all non-ALE1 assets to a new entity. BioMarin’s acquisition of Alesta was structured to retain the ALE1 asset within Alesta.

Does the CASIF filing include forward-looking statements related to this transaction?

Yes. The announcement includes forward-looking statements under the U.S. Private Securities Litigation Reform Act of 1995, noting that actual results may differ due to various risks discussed in CASI Pharmaceuticals’ SEC filings.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/02/2026 - 07:01 AM EDT Accepted by SEC EDGAR 09/02/2026 - 07:00 AM EDT Learn about SEC filing dates

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE
13a-16 OR 15d-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934

For the month of September, 2026

Commission File Number  001-41666

CASI PHARMACEUTICALS, INC.

(Translation of registrant’s name into English)

1701-1702, China Central Office Tower 1

No. 81 Jianguo Road, Chaoyang District

Beijing, 100025

People’s Republic of China

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.  Form 20-F  x Form 40-F  ¨

INCORPORATION BY REFERENCE

The information included in this Report on Form 6-K is hereby incorporated by reference into the Company's Registration Statements on Form F-3 (File No. 333-283998 and No. 333-281621) (including any prospectuses forming a part of such registration statement) and is to be a part thereof from the date on which this Report on Form 6-K is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

CASI Pharmaceuticals Announces Sale of Equity Interests in Alesta

CASI Pharmaceuticals, Inc. (OTCQB: CASIF, the “Company”), a clinical-stage biopharmaceutical company developing CID-103, an anti-CD38 monoclonal antibody, for patients with organ transplant rejection and autoimmune diseases, today reported that the Company sold its equity interests in Alesta Therapeutics B.V. (“Alesta”) to BioMarin Pharmaceutical Inc. (“BioMarin”) in connection with BioMarin’s acquisition of Alesta pursuant to a Share Purchase Agreement. The transaction closed on August 31, 2026.

Under the terms of the transaction agreement, the Company received approximately US$5.9 million in net cash proceeds at closing, and may be entitled to receive its allocable portion of additional contingent payments upon the achievement of specified development and regulatory milestones. Any such future payments are subject to the terms and conditions of the transaction agreement and are not assured. The Company will make further announcements accordingly when and if such payments are received.

BioMarin’s acquisition of Alesta was structured to retain ALE1 within Alesta. Prior to the closing, Alesta completed the spin-out of all non-ALE1 assets to a new entity. The Company’s existing licensed rights to CID-103 remain unchanged as a result of the transaction.

Forward-Looking Statements

This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," "confident" and similar statements. Among other things, the business outlook and quotations from management in this announcement, as well as the Company's strategic and operational plans, contain forward-looking statements. The Company may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission (the "SEC"), in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about the Company's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement. Further information regarding these and other risks is included in the Company's filings with the SEC. All information provided herein is as of the date of this announcement, and the Company undertakes no obligation to update any forward-looking statement, except as required under applicable law. We caution readers not to place undue reliance on any forward-looking statements contained herein.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	CASI Pharmaceuticals, Inc.
	By:	/s/ Wei-Wu He
	Name:	Wei-Wu He
	Title:	Chairman to the Board
Date: September 2, 2026